PMID- 34606729
OWN - NLM
STAT- MEDLINE
DCOM- 20220224
LR  - 20240403
IS  - 1555-3892 (Electronic)
IS  - 0963-6897 (Print)
IS  - 0963-6897 (Linking)
VI  - 30
DP  - 2021 Jan-Dec
TI  - Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting 
      the PD-1/PD-L1 axis for Clinical Management of NSCLC.
PG  - 9636897211041587
LID - 10.1177/09636897211041587 [doi]
LID - 09636897211041587
AB  - Non-small-cell lung cancer takes up the majority of lung carcinoma-caused deaths. 
      It is reported that targeting PD-1/PD-L1, a well-known immune evasion checkpoint, 
      can eradicate tumor. Checkpoint inhibitors, such as monoclonal antibodies, are 
      actively employed in cancer treatment. Thus, this review aimed to assess the 
      therapeutic and toxic effects of PD-1/PD-L1 inhibitors in treatment of NSCLC. So 
      far, 6 monoclonal antibodies blocking PD-1/PD-L1 interaction are identified and 
      used in clinical trials and randomized controlled trials for NSCLC therapy. These 
      antibody-based therapies for NSCLC were collected by using search engine PubMed, 
      and articles about the assessment of adverse events were collected by using 
      Google search. Route of administration and dosage are critical parameters for 
      efficient immunotherapy. Although antibodies can improve overall survival and are 
      expected to be target-specific, they can cause systemic adverse effects in the 
      host. Targeting certain biomarkers can limit the toxicity of adverse effects of 
      the antibody-mediated therapy. Clinical experts with knowledge of adverse effects 
      (AEs) of checkpoint inhibitors can help manage and reduce mortalities associated 
      with antibody-based therapy of NSCLC.
FAU - Chen, Jing
AU  - Chen J
AD  - Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, 
      Southeast University, Dingjiaqiao 87, Gulou District, Nanjing, 210009, Jiangsu, 
      China.
FAU - Alduais, Yaser
AU  - Alduais Y
AD  - Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, 
      Southeast University, Dingjiaqiao 87, Gulou District, Nanjing, 210009, Jiangsu, 
      China.
FAU - Chen, Baoan
AU  - Chen B
AUID- ORCID: 0000-0003-1490-1259
AD  - Department of Hematology and Oncology, Zhongda Hospital, School of Medicine, 
      Southeast University, Dingjiaqiao 87, Gulou District, Nanjing, 210009, Jiangsu, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United States
TA  - Cell Transplant
JT  - Cell transplantation
JID - 9208854
RN  - 0 (Immune Checkpoint Inhibitors)
SB  - IM
MH  - Animals
MH  - Carcinoma, Non-Small-Cell Lung/*complications/drug therapy/pathology
MH  - Humans
MH  - Immune Checkpoint Inhibitors/*adverse effects
MH  - Lung Neoplasms/*complications/drug therapy/pathology
MH  - Mice
PMC - PMC8493325
OTO - NOTNLM
OT  - NSCLC
OT  - PD-1/PD-L1
OT  - checkpoint inhibitors
OT  - monoclonal antibodies
OT  - toxicity
COIS- Declaration of Conflicting Interests: The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2021/10/05 06:00
MHDA- 2022/02/25 06:00
PMCR- 2021/10/04
CRDT- 2021/10/04 20:11
PHST- 2021/10/04 20:11 [entrez]
PHST- 2021/10/05 06:00 [pubmed]
PHST- 2022/02/25 06:00 [medline]
PHST- 2021/10/04 00:00 [pmc-release]
AID - 10.1177_09636897211041587 [pii]
AID - 10.1177/09636897211041587 [doi]
PST - ppublish
SO  - Cell Transplant. 2021 Jan-Dec;30:9636897211041587. doi: 
      10.1177/09636897211041587.